Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (enterocytes) | 0.10 |
| chemistry Open Targets | compounds already reach it: cilazapril, enalapril maleate, perindopril arginine +21 | 1.00 |
| trials ClinicalTrials.gov | 12 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 193 Parkinson's papers of 48,049 | 0.31 |
| pathways Reactome | 1 pathway; mostly energy | 0.60 |
No case: the score is under the bar. Receipt 3683
Sealed predictions
- ACE in dopamine neurons, braak+0.29 (p 0.443) → -0.69 (p 0.040)receipt 3690
Swarm cases
receipt 3690: ACE in dopamine neurons, braak
- power
- full sample -0.27 (p 0.281, n 18), 95% CI -0.65 to +0.23. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.27 (p 0.281, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.39 (p 0.109, n 18). could be the mix.
- skeptic
- leave-one-out range -0.40 to -0.17, sign flips 0; without severely affected donors -0.27 (p 0.281, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ACE in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts